Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension safety study of tocilizumab (RoActemra) in early moderate to severe rheumatoid arthritis
2011-006125-14Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Long-term safety of tocilizumab. Started Mar 2012; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-006125-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006125-14.